- PROCTO3 REPORT AT Gastroenterology, Hepatobiliary, and Biliary Department - FV HOSPITAL (17/01/2024 )
- GLIGCA REPORT AT SPINE DEPARTMENT B – HCMC ORTHOPEDIC TRAUMA HOSPITAL (17/01/2024 )
- REPORT TAMDEFLO, CAPSER, VOCFOR, DEGODAS CAN THO CENTRAL GERD (17/01/2024 )
- CAPSER REPORT FOR MUSCULOSCOPIC AND JOINT DEPARTMENT OF CHO RAY HOSPITAL (17/01/2024 )
- TAMDEFLO MINH DUC HOSPITALOn October 21, 2023, Medbolide Joint Stock Company had a report to introduce the product TAMDEFLO (deflazacort 6mg) at the hall of Minh Duc Hospital, Ben Tre. The report took place with the participation of more than 30 Doc (17/01/2024 )
- Report TAMDEFLO Thong Nhat Hospital (17/01/2024 )
- Report TAMDEFLO MEDIC BINH DUONG (17/01/2024 )
- GLIGCA REPORT AT THE PHARMACY DEPARTMENT - FV HOSPITAL (11/01/2024 )
- CAPSER – ENDOCRINE DEPARTMENT, CHO RAY HOSPITAL (16/10/2023 )
- Report CAPSER, DEGODAS – JOINT DEPARTMENT OF ORTHOPEDIC TRAUMA HOSPITAL (16/10/2023 )
REPORT TAMDEFLO ORTHOPEDIC TRAUMA DEPARTMENT
November 16, 2023, at the upper limb department, Orthopedic Trauma Hospital.
Medbolide Joint Stock Company had a report introducing the product TAMDEFLO (deflazacort 6mg). The report took place with the participation of more than 30 Doctors and medical staff.
Company representatives presented recommendations and clinical research demonstrating the effectiveness of the active ingredient deflazacort, which belongs to the corticoids group. The outstanding advantage of deflazacort is that it helps limit the typical side effects of corticosteroids.
Medbolide hopes to bring the best treatment options to patients, contributing to improving the health of the community.
Readers comments